Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Internet Revolution: Implications for Pharma

This article was originally published in Start Up

Executive Summary

Big Pharma has been generally cautious in developing Internet capabilities and strategies: most companies are only selectively applying Web technologies to their existing business models. The Internet opens many potential opportunities for drug companies, including streamlining procurement & manufacturing, sharing R&D knowledge through virtual communities, enhancing clinical development productivity, and developing new techniques for marketing to consumers and physicians. To design and execute an effective Internet strategy, companies need to develop in-house capabilities in six categories: continuous strategy development; rapid decisionmaking and resource allocations; e-commerce dealmaking; best in market sourcing; technology architecture; and performance-driven management.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

SC090134

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel